Report Examines Expanding North American Cannabis Market place


The cannabis industry in North American will be worth $47.three billion by 2024, a new report shows.

The report out this week paints a portrait of the cannabis market in the U.S. and Canada that “is developing at an explosive price, fueled by progressive legislative adjustments, innovation and a burgeoning industrial industry.”

The North American Cannabis Report, which was issued by Prohibition Partners, a information and intelligence provider founded in 2017, forecasts medicinal and recreational cannabis will be legalized across North America and integrated across several market verticals from pharma to meals in coming years.

Canada has currently legalized recreational use, and in the U.S. bills that would legalize and tax marijuana at the national level, and present possibilities for persons convicted of federal pot crimes to clear their records, have been introduced in Congress.

“If cannabis is legalized in all states of the U.S. by 2024, the total worth for cannabis could be approaching the $50 billion mark,” the report states.

California alone is set to be a major contributor to that prospective development.

A report focused on California release final month shows the state’s industry is on track to hit $7.two billion in 2024 on the back of an anticipated 19% compound annual development price.

The state’s cannabis market has grown regardless of most nearby governments sitting on the sidelines of California’s cannabis rush.

The report appears at the 11 states, plus Washington, D.C., which have legalized recreational use cannabis, and the 33 states that have legalized healthcare use cannabis.

Prospective legalization is afoot on other states. The report calls out Minnesota, exactly where there are ongoing efforts to approve legislation that would permit Minnesotans aged 21 and more than to possess and use cannabis recreationally, and Arizona, exactly where “it is extensively regarded as inevitable” the state is going to legalize recreational use.

A Pew Analysis Center poll in 2018 showed 62% of Americans supported legalizing cannabis.

According to the Prohibition Partners report, there are variations in generational viewpoints on legalization in the U.S.

A vast majority of Millennials (74%) are for legalization, followed by Gen Xers (63%) and Infant Boomers (54%).

Almost seven out of 10 Democrats say cannabis use need to be legal compared to Republicans with 51% opposed to legalizing cannabis.

In each the U.S. and Canada, 22% of persons say they applied recreational cannabis more than the previous year, according to the report.

Other intriguing highlights from the report consist of profiles of standard customers in the U.S.:

  • Most persons who use cannabis are parents
  • A total of 25% of millennial cannabis customers say they really feel “guilty” about their cannabis habit, compared with 17% of non-millennials.
  • The majority of cannabis customers are male, educated beneath degree level and earn below $50,000 a year.
  • About 35 million are “regular users” (at least as soon as or twice a month).
  • Roughly 28% would use cannabis if the federal government legalized it nationally. The rest stated the legal transform wouldn’t make considerably of a distinction in their behavior.

A significant portion of the report appears at medicinal use, with “key healthcare opportunities” which includes treating addiction with CBD and aiding sleep issues.

Alleviating chronic discomfort is 1 of the largest locations of prospective for healthcare cannabis, the report notes.

“Data from the Centers for Illness Handle and Prevention (CDC) estimates that 50 million Americans endure from chronic discomfort, and 20 million of them endure from discomfort so serious that it limits life or operate activities,” the report notes. “Research carried out by Yahoo News/Marist College in a 2017 survey located that virtually 1 in 5 (19%) cannabis customers use it to relieve discomfort, and this highlights the strategies in which cannabis is presently becoming applied for medicinal purposes. As of March 2019, two US states, New York and Illinois, have legalized the use of cannabis as an option to addictive opioids to assistance treat chronic discomfort.”

The report also shows concentrates and vapes to be the crucial development categories, although solutions with greater dosages of CBD (Cannabidiol, a non-intoxicating cannabinoid in the cannabis plant that is becoming viewed as a remedy for anxiousness, discomfort, and other healthcare maladies) are getting into the industry.

“Topical and transdermal cannabis formulations are a development location and are as eye-catching to the little niche players as they are to the key organizations,” the report states.


Want to remain up to date?

Get the most recent insurance coverage news
sent straight to your inbox.


Latest posts